Literature DB >> 12638822

Trans-hiatal oesophagectomy as palliative treatment for carcinoma of the oesophagus.

V O Adegboye1, M O Obajimi, A O Ogunseyinde, I A Brimmo, A O Adebo.   

Abstract

OBJECTIVE: To determine the role of palliation with trans-hiatal oesophagectomy in Nigerian patients with carcinoma of the oesophagus.
DESIGN: Prospective case series. The first series was from February 1986 to September 1987 (Series A) while the second series was from March 1989 to November 1996 (Series B).
SETTING: Cardiothoracic Surgery Unit (CTSU) of the University College Hospital, Ibadan, Nigeria.
SUBJECTS: First series consisted of 10 consecutive operable patients with carcinoma of oesophagus seen over the period of study. The second series consisted of 21 consecutive patients with same disease. INTERVENTION: All patients had transhiatal oeosphagectomy by a two team approach and immediate placement of the freed stomach in the posterior mediastinum and cervical oesophagogastrostomy.
RESULTS: Patients in both series had a comparable age range of 43 - 80 years for series A and 40 - 82 years for Series B. The duration of symptoms were 2 - 6 months and 2 - 12 months respectively, for series A and B. In series A, nine patients had carcinoma of the middle-third (M1/3) of the thoracic oesophagus and one patient had carcinoma of lower-third (L1/3) of the thoracic oesophagus. In series B, 18 patients had M1/3 and three patients had L1/3 lesions. Average blood loss in series A was 1,067 mls, corresponding value for series B was 852 mls. Postoperatively, all cases were classified as stage III or stage IV disease. There were 18 complications in eight patients in series A and 22 complications in 10 patients in series B. The commonest complications in series A were pleural enteries in six patients, haemorrhage four patients (three intraoperative, one post-operative) and respiratory failure (two patients). The commonest in series B were pleural enteries in nine patients, anastomotic leaks and stenosis in four patients and respiratory failure in three patients. Hospital mortality was 50% in Series A and 14.3% in series B. The causes of death were haemorrhage and respiratory failure in series A, respiratory failure in series B. Survival period in series A of the five patients discharged was for a median of 84 months, for series B, four patients were alive at 18 months post-operative, one patient attended follow-up clinic 24 months after surgery. No other adjunctive therapy was offered to the patients.
CONCLUSION: Trans-hiatal oesophagectomy is a procedure suitable for patients with carcinoma of the oesophagus and affords palliation at an "acceptable price" among carefully selected patients with advanced carcinoma of the oesophagus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12638822     DOI: 10.4314/eamj.v79i6.8851

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  4 in total

Review 1.  Survival after oesophagectomy for cancer of the oesophagus.

Authors:  Hubert J Stein; Burkhard H A von Rahden; J Rüdiger Siewert
Journal:  Langenbecks Arch Surg       Date:  2004-07-14       Impact factor: 3.445

2.  Systematic review and meta-analysis of esophageal cancer in Africa: Epidemiology, risk factors, management and outcomes.

Authors:  Akwi W Asombang; Nathaniel Chishinga; Alick Nkhoma; Jackson Chipaila; Bright Nsokolo; Martha Manda-Mapalo; Joao Filipe G Montiero; Lewis Banda; Kulwinder S Dua
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

3.  Endoscopic and clinicopathological patterns of esophageal cancer in Tanzania: experiences from two tertiary health institutions.

Authors:  Mabula D McHembe; Peter F Rambau; Phillipo L Chalya; Hyasinta Jaka; Mheta Koy; William Mahalu
Journal:  World J Surg Oncol       Date:  2013-10-04       Impact factor: 2.754

4.  Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends.

Authors:  Daniel R S Middleton; Liacine Bouaoun; Rachel Hanisch; Freddie Bray; Charles Dzamalala; Steady Chasimpha; Diana Menya; Charles Gombé Mbalawa; Guy N'Da; Mathewos A Woldegeorgis; Ramou Njie; Moussa Koulibaly; Nathan Buziba; Josefo Ferro; Hassan Nouhou; Femi Ogunbiyi; Henry R Wabinga; Eric Chokunonga; Margaret Z Borok; Anne R Korir; Amos O Mwasamwaja; Blandina T Mmbaga; Joachim Schüz; Valerie A McCormack
Journal:  Cancer Epidemiol       Date:  2018-02-06       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.